

# Wencheng Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10066573/publications.pdf>

Version: 2024-02-01

51  
papers

874  
citations

567281

15  
h-index

552781

26  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1020  
citing authors

#	ARTICLE	IF	CITATIONS
1	Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. <i>Oncolmmunology</i> , 2022, 11, 2025668.	4.6	6
2	Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002). <i>Frontiers in Oncology</i> , 2022, 12, 831345.	2.8	18
3	Age plays an important role in the decision of definitive concurrent chemoradiotherapy (CCRT) for esophageal squamous cell carcinoma (ESCC): a propensity-score matched analysis of multicenter data (3JECROG R-02A). <i>Translational Cancer Research</i> , 2021, 10, 0-0.	1.0	1
4	Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. <i>Oncolmmunology</i> , 2021, 10, 1971418.	4.6	36
5	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. <i>Acta OncolÃ³gica</i> , 2021, 60, 627-634.	1.8	13
6	Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China. <i>Radiation Oncology</i> , 2021, 16, 102.	2.7	8
7	Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1110-e1124.	3.7	56
8	A Clinical Scoring Model to Predict the Effect of Induction Chemotherapy With Definitive Concurrent Chemoradiotherapy on Esophageal Squamous Cell Carcinoma Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 703074.	2.8	1
9	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110619.	3.2	3
10	Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 786429.	4.8	12
11	Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1193-1193.	1.7	25
12	Concurrent or Sequential Chemoradiotherapy after 3-4 Cycles Induction Chemotherapy for LS-SCLC with Bulky Tumor. <i>Journal of Cancer</i> , 2020, 11, 4957-4964.	2.5	2
13	Stage III Esophageal Squamous Cell Carcinoma Patients With Three-Dimensional Conformal or Intensity-Modulated Radiotherapy: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 580450.	2.8	3
14	Annual report of the esophageal cancer radiation group of the Department of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital. <i>Annals of Translational Medicine</i> , 2020, 8, 1156-1156.	1.7	1
15	Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patients. <i>Annals of Translational Medicine</i> , 2020, 8, 1163-1163.	1.7	12
16	S-1â€‘Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. <i>Frontiers in Oncology</i> , 2020, 10, 1499.	2.8	9
17	The efficacy and safety of simultaneous integrated dose reduction in clinical target volume with intensity-modulated radiotherapy for patients with locally advanced esophageal squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1160-1160.	1.7	3
18	Is There a Role for Post-Mastectomy Radiotherapy for T1-2N1 Breast Cancers With Node-Positive Pathology After Patients Become Node-Negative Pathology Following Neoadjuvant Chemotherapy?. <i>Frontiers in Oncology</i> , 2020, 10, 892.	2.8	7

#	ARTICLE	IF	CITATIONS
19	A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIb/III esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 130.	2.6	10
20	Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study. <i>Oncologist</i> , 2020, 25, e1464-e1472.	3.7	20
21	Baseline nutritional status could be a predictor for radiation esophagitis in esophageal cancer patients undergoing radiotherapy. <i>Annals of Translational Medicine</i> , 2020, 8, 1148-1148.	1.7	10
22	Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1152-1152.	1.7	6
23	Role of clip markers placed by endoscopic ultrasonography in contouring gross tumor volume for thoracic esophageal squamous cell carcinoma: one prospective study. <i>Annals of Translational Medicine</i> , 2020, 8, 1144-1144.	1.7	1
24	Safety and efficacy of programmed cell death-1 antibody SHR-1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory single-arm phase Ib trial. <i>Precision Radiation Oncology</i> , 2020, 4, 113-119.	1.1	0
25	The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy. <i>Aging</i> , 2020, 12, 6586-6599.	3.1	4
26	Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03). <i>Annals of Translational Medicine</i> , 2020, 8, 1140.	1.7	1
27	Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03). <i>Annals of Translational Medicine</i> , 2020, 8, 1140-1140.	1.7	1
28	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. <i>Radiotherapy and Oncology</i> , 2019, 140, 159-166.	0.6	16
29	Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 10497.	3.3	6
30	Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 319-328.	0.8	22
31	<p>Clinical results of intensity-modulated radiotherapy for 250 patients with cervical and upper thoracic esophageal carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8285-8294.	1.9	2
32	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2890-2898.	1.5	28
33	A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol. <i>BMC Cancer</i> , 2019, 19, 397.	2.6	12
34	Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study. <i>Thoracic Cancer</i> , 2019, 10, 1431-1440.	1.9	10
35	Chemoradiotherapy-Induced CD4+ and CD8+ T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 73.	2.8	17
36	Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6333-6338.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 274-280.	0.6	38
38	The Impact of Postoperative Conformal Radiotherapy After Radical Surgery on Survival and Recurrence in Pathologic T3N0M0 Esophageal Carcinoma: A Propensity Score-Matched Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1143-1151.	1.1	35
39	Programmed death ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. <i>Cancer Science</i> , 2017, 108, 590-597.	3.9	37
40	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 401-405.	0.6	73
41	Radiomics predicts clinical outcome in primary gastroesophageal junction adenocarcinoma treated by chemo/radiotherapy and surgery. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 3, 37-42.	2.9	10
42	Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, e172032.	7.1	119
43	Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 763-771.	2.0	39
44	Treatment of esophageal cancer with radiation therapy: a pan-Chinese survey of radiation oncologists. <i>Oncotarget</i> , 2017, 8, 34946-34953.	1.8	6
45	Prognostic value of supraclavicular nodes and upper abdominal nodes metastasis after definitive chemoradiotherapy for patients with thoracic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 65171-65185.	1.8	4
46	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy. <i>Oncotarget</i> , 2016, 7, 55211-55221.	1.8	13
47	Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma. <i>Thoracic Cancer</i> , 2015, 6, 597-604.	1.9	15
48	Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy. <i>Radiation Oncology</i> , 2015, 10, 142.	2.7	11
49	Postoperative Intensity-Modulated Radiotherapy Improved Survival in Lymph Node-Positive or Stage III Thoracic Esophageal Squamous Cell Carcinoma. <i>Oncology Research and Treatment</i> , 2015, 38, 97-102.	1.2	31
50	Associations of ATM Polymorphisms With Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Receiving Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 181-189.	0.8	4
51	Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma. <i>Annals of Thoracic Surgery</i> , 2014, 98, 513-519.	1.3	46